Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation

Autor:	William Gennari, Ad Pinna, F. Di Benedetto, Nicola Cautero, Roberto Esposito, Mauro Codeluppi, Stefano Bonora, Giorgio Enrico Gerunda, Stefania Cocchi, Monica Pecorari, Giovanni Guaraldi
Jazyk:	angličtina
Rok vydání:	2005
Předmět:	Adult Male medicine.medical_specialty Anti-HIV Agents medicine.medical_treatment Hepatitis C virus therapeutic drug monitoring HIV Infections medicine.disease_cause Gastroenterology Liver disease orthotopic liver transplantation Recurrence Internal medicine Antiretroviral Therapy Highly Active medicine Humans Transplantation HIV Maintenance dose business.industry virus diseases Lamivudine Immunosuppression Lopinavir medicine.disease Hepatitis C Tacrolimus Liver Transplantation Treatment Outcome Immunology Surgery Ritonavir Drug Monitoring business Liver Failure medicine.drug
Popis:	Pharmacological interactions between protease inhibitors and tacrolimus require careful monitoring to prevent toxicity in the posttransplantation period. A 42-year-old man with human immunodeficiency virus (HIV) infection and end-stage liver disease due to hepatitis C virus (HCV) received an orthotopic liver transplant. At the time of surgery the patient was on triple antiretroviral therapy (tenofovir, lamivudine, and lopinavir/ritonavir) with a stable CD4 + count (>500 cells/mm 3 ) and HIV-1 RNA (
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2325cbb44ae6c8ec11cac8eb425f12ad http://hdl.handle.net/2318/32081 Zobrazit plný text záznamu